Chapman Rowan E sold $37K of NTRA
Chapman Rowan E sold 135 shares of Natera, Inc. (NTRA) at $274.82 on 2026-07-15 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
A director’s small open-market sale under a 10b5-1 plan is typically treated as low-signal for fundamentals, but it can be used for monitoring insider activity trends.
Market read
Traders may log this as routine insider activity; it is unlikely to drive a major repricing without additional catalysts.
What to watch
The article provides only the sale details and not total insider holdings changes beyond the post-transaction share count, limiting inference about broader insider sentiment.
Background
The article is an SEC Form 4 insider transaction disclosure for Natera, Inc.
Ticker impact
Natera director Chapman Rowan E filed a Form 4 open-market sale of 135 shares at $274.82 on 2026-07-15 under a 10b5-1 plan.
Low likelihood of a sustained price move solely from this Form 4 sale.
The filing is an open-market sale by a director, explicitly under a pre-arranged Rule 10b5-1 plan, and the disclosed value ($37.1K) is small relative to typical company market impact.
Market effects
Minimal. Routine insider selling under 10b5-1 does not materially change the diagnostics/oncology read-through.
None indicated.
None indicated.
Counterpoint
Even planned sales can coincide with internal views on near-term risk, so some traders may still watch for follow-on insider activity or changes in trading patterns.
Key entities
- issuerNatera, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderChapman Rowan E
Director who sold 135 shares at $274.82 per share under a Rule 10b5-1 plan.
